Professionals 215 Users Online

Orally Disintegrating Tablet Market

Global Market Study on Orally Disintegrating Tablet: Convenience of usage to drive market expansion

Orally Disintegrating Tablet Market Segmented By Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitors Drug Class with CNS Diseases, GI Diseases, CVS Disorders, Allergy Disease Indication

Orally Disintegrating Tablet Market Outlook (2022 - 2025)

The Global Orally Disintegrating Tablet Market value is projected to exceed US$ 19,627.4 million by the year 2025 at a CAGR of 8.5%. The oral route of drug administration is the usual approach in the pharmaceutical business since it is the most cost-effective, easier, and safer way of drug administration. The tablets are normally taken with water.

The oral tablets enter the gastrointestinal tract and are immediately absorbed into the bloodstream. However, the orally disintegrating tablets are solid dosage forms that quickly dissolve in the mouth and do not require water to ingest. Orally disintegrating tablets are increasingly being used as an alternative to traditional tablets or capsules.

Attribute Key Insights

Orally Disintegrating Tablet Market Size (2022)

US$ 19,627.4 Mn

Projected Market Value (2025)

US$ 27,222.9 Mn

Global Market Growth Rate (2022-2025)

8.5% CAGR

Share in parent market

22%

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Orally Disintegrating Tablet Market Demand Analysis (2012-2021) v/s Market Outlook (2022 – 2025)

The Orally Disintegrating Tablet Market is likely to have a CAGR of 8.5% over the forecast period. One of the primary factors driving the growth of Orally Disintegrating Tablets is that these tablets are increasingly being used as an alternative to traditional tablets or capsules. Apart from this, the rising adoption of technologically improved products and an increase in the prevalence of CNS illnesses such as depression, migraine, Parkinson's disease, Alzheimer's disease, and schizophrenia are likely to drive market growth.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What is expected to keep the Hopes High for Orally Disintegrating Tablet Market?

“Increased Adoption of Orally Disintegrating Tablet ”

Because of improved patient compliance, orally disintegrating tablets (ODTs) are being increasingly adopted over the last few years as a preferable substitute to traditional tablets and capsules. Orally disintegrating tablets dissolve in the mouth within minutes and do not require water to ingest. Traditional medications are difficult to swallow for infants, young children, and elderly people. To address such complications, various orally disintegrating pills with increased performance are developed and launched. Furthermore, advancements like enhanced taste and disintegration are enhancing ODT adoption.

orally-disintegrating-tablet-market

“Enhanced Drug Bioavailability”

The concentration of the medicines taken orally is substantially lowered medication before it reaches the bloodstream and this is where the capacity of Orally Disintegrating Tablets to avoid first-pass metabolism helps solve such difficulties. Orally disintegrating tablets with enhanced bioavailability for protein and peptide-based therapies are a viable alternative for delivering high molecular weight medicines and this factor is likely to drive the growth of the Orally Disintegrating Tablet Market in the coming years.

“Rise in Clinical Trials”

Over the last few years, the popularity of ODTs has increased significantly. The growing number of clinical trials and clinical research are increasing the investment in developing better quality orally disintegrating tablets, and it is likely to improve market growth in the near future.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Competitive Landscape

The Orally Disintegrating Tablet market is highly fragmented and consists of several major and new market players. The market players are focusing on discovering NCEs and excipients for rare diseases along with developing novel formulations to extend the patent regime.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Orally Disintegrating Tablet Market Industry Report Scope

Attribute Details

Forecast Period

2022-2025

Historical Data Available for

2012-2021

Market Analysis

US$ Mn/Bn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Covered

  • U.S.
  • Canada
  • Germany
  • Italy
  • France
  • U.K.
  • Spain
  • Russia
  • India
  • China
  • Japan
  • UAE
  • Australia

Key Market Segments Covered

By Distribution Channel

Key Companies Profiled

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • AstraZeneca
  • Mylan N.V.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bausch Health
  • GlaxoSmithKline plc.
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Eli Lily and Company
  • Dr. Reddy’s Laboratories Ltd.
  • Takeda Pharmaceutical Company Limited

Customization & Pricing

Available upon Request

Orally Disintegrating Tablet Market Categorization

Orally Disintegrating Tablet Market By Drug Class

  • Anti-Psychotics
  • Anti-Epileptics
  • CNS Stimulants
  • Anxiolytics
  • Anti-Parkinsonian Drugs
  • Anti-Hypertensives
  • NSAIDS
  • Anti-Allergy Drugs
  • Proton Pump Inhibitors
  • Others

Orally Disintegrating Tablet Market By Disease Indication

  • CNS Diseases
  • GI Diseases
  • CVS Disorders
  • Allergy
  • Others

Orally Disintegrating Tablet Market By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Orally Disintegrating Tablet Market By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

- Companies Covered in This Report -

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • AstraZeneca
  • Mylan N.V.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bausch Health
  • GlaxoSmithKline plc.
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Eli Lily and Company
  • Dr. Reddy’s Laboratories Ltd.
  • Takeda Pharmaceutical Company Limited

- Frequently Asked Questions -

In 2022, the Orally Disintegrating Tablet Market stands at USD 19,627.4 million, and it is expected to reach USD 27,222.9 million by 2025 at a CAGR of 8.5%.

Orally Disintegrating Tablet Market exhibited a 11.4% CAGR between 2012 and 2021.

Increased adoption of orally disintegrating tablets is the key factor driving the growth of the market.

Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Mylan N.V., and Pfizer Inc., are among the top players in the market.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate